Saturday 17 October 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024. In the quarter to June 2026, revenue grew 16.5%, EPS fell 40.0%, free cash flow grew 31.6% and total debt rose 12.0%, each against the same quarter a year earlier. Dividend growth for five consecutive years.

61.29 1.67 +2.80%

Follow RPRX

Alert me

Market cap: $34.3B
P/E: 42.3×
Fwd P/E: 21.9×
Dividend yield: 1.51%
F-score: 5/9
Altman Z: 1.61
Beneish M: −2.83
Dividend safety: 37/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 92.82

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	3	9	7	2	2	2	4	3	1	2	2	1

Insider Ownership 6.27%

Capital & Financial Ratios $m

Market Cap 34,280.00

Revenue 2,536.00

Net Income 1,346.87

Free Cash Flow 1,310.08

Net Debt 8,124.91

Current Ratio 2.80

Debt/Equity 0.92

P/E ratio 42.27

Fwd P/E 21.90

P/S ratio 10.76

P/B ratio 2.79

Past 5Y EPS Growth (3.18%)

This Y EPS Growth 10.17%

Next Y EPS Growth 8.99%

Next Y revenue growth 47.38%

Next 5Y EPS Growth 10.64%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 69.80%

10-year low 10-year high

P/S against its own 10 years 99.31%

10-year low 10-year high

P/B against its own 10 years 99.31%

10-year low 10-year high

EV/Sales against its own 10 years 99.31%

10-year low 10-year high

EV/FCF against its own 10 years 73.34%

10-year low 10-year high

Dividends

Payout Ratio 0.64

Annual Dividend Rate 0.93

Annual Dividend Yield 1.51%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	1.01	0.24 0.24 0.24
2025	0.88	0.22 0.22 0.22 0.22
2024	0.84	0.21 0.21 0.21 0.21
2023	0.80	0.20 0.20 0.20 0.20
2022	0.76	0.19 0.19 0.19 0.19
2021	0.68	0.17 0.17 0.17 0.17
2020	0.30	0.15 0.15

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	495	987	637	837
Receivables	22	27	29	31
Inventory	—	—	—	—
Other	756	788	861	896
	1,274	1,802	1,528	1,765

	2023	2024	2025	Q'26
Payables	15	13	19	36
ST’ Debt	—	998	380	380
Other	11	69	53	16
	161	1,254	636	631

Compound Annual Growth %

	10y	5y	3y
Sales	—	2.30%	2.06%
Cash Flow	—	4.12%	5.11%
Earnings	—	(4.59%)	162.07%
Book Value	—	(0.37%)	0.66%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	631	674	—	—	—
’25	568	579	609	622	2,378
’24	568	537	565	594	2,264
’23	684	538	536	596	2,355
’22	562	536	573	566	2,237
’21	573	555	586	576	2,289
’20	501	511	538	572	2,122

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	718	728	—	—	—
’25	596	364	703	827	2,490
’24	665	658	704	743	2,769
’23	1,034	608	574	773	2,988
’22	460	575	539	570	2,144
’21	526	532	470	490	2,018
’20	471	489	509	566	2,035

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	266	477	—	—	—
’25	595	363	(259)	827	2,490
’24	579	(70)	(491)	2,734	2,751
’23	432	547	122	773	2,988
’22	460	400	(777)	2,040	2,123
’21	23	351	(866)	318	(174)
’20	372	14	(294)	(239)	(148)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.53	0.03	—	—	—
’25	0.41	0.05	0.51	0.38	1.37
’24	0.01	0.17	0.92	0.35	1.45
’23	0.56	0.38	0.12	0.83	1.88
’22	0.09	0.50	0.24	(0.86)	0.07
’21	0.11	0.73	0.17	0.01	1.02
’20	—	0.73	0.48	0.28	1.61

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	34.80	34.86	36.15	25.92	24.05	25.40	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	56.50	53.23	44.75	39.92	31.66	41.24
People
People	Employees	—	—	—	35	—	—	—	89	99	100
	Revenue/emp, $m	—	—	0.00	51.84	0.00	0.00	0.00	26.46	22.86	23.78
Income, $m
Income, $m	Revenue	—	—	1,795	1,814	2,122	2,289	2,237	2,355	2,264	2,378
	Gross margin, %	—	—	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	1,518	2,461	1,702	1,241	230	1,700	1,331	1,324
	EBT margin, %	—	—	84.57	135.67	80.19	54.21	10.28	72.20	58.79	55.68
	Net income	—	0	1,518	2,461	1,702	1,241	230	1,700	1,331	1,324
	Depreciation	—	—	46	37	35	43	27	20	20	32
Per share, $
Per share, $	Revenue	—	—	0.00	4.83	5.65	5.52	5.11	5.26	5.05	5.53
	Earnings	—	—	—	6.56	1.61	1.02	0.07	1.88	1.45	1.37
	Cash flow	—	—	0.00	4.44	5.42	4.86	4.90	6.68	6.18	5.79
	Capex	—	—	0.00	(4.58)	(5.81)	(5.28)	(0.05)	0.00	(0.04)	0.00
	Free cash flow	—	—	0.00	(0.14)	(0.39)	(0.42)	4.85	6.68	6.14	5.79
	Book value	—	—	0.00	16.36	26.36	24.71	21.75	22.53	23.08	22.60
	Shares, m	—	—	—	375	375	415	438	448	448	430
Valuation, ×
Valuation, ×	P/E	—	—	66.51	66.51	41.36	39.07	492.50	14.96	17.59	28.62
	P/S	—	—	0.00	0.00	8.85	7.22	7.71	5.37	5.05	6.98
	P/B	—	—	0.00	0.00	1.90	1.61	1.81	1.25	1.11	1.71
	EV/Sales	—	—	0.00	0.00	10.71	9.44	10.12	8.19	7.98	10.48
	EV/FCF	—	—	18.65	18.65	(153.96)	(124.27)	10.66	5.77	6.56	7.09
Cash, $m
Cash, $m	Operating cash flow	—	—	1,618	1,667	2,035	2,018	2,144	2,988	2,769	2,490
	Capex	—	—	(270)	(1,721)	(2,182)	(2,192)	(21)	—	(18)	—
	Free cash flow	—	—	1,349	(54)	(148)	(174)	2,123	2,988	2,751	2,490
Balance, $m
Balance, $m	Working capital	—	—	—	499	2,389	2,707	1,388	1,113	549	892
	Total debt	—	—	—	6,266	5,817	7,096	7,116	6,135	7,612	8,951
	Net debt	—	—	—	5,926	3,755	4,907	5,380	5,640	6,625	8,313
	Shareholders’ equity	—	—	—	6,141	9,896	10,249	9,525	10,084	10,342	9,715
Returns, %
Returns, %	ROA	—	—	0.00	37.73	6.85	3.70	0.25	6.84	4.96	4.07
	ROIC	—	—	0.00	13.59	7.30	5.90	1.29	5.93	4.76	5.41
	ROE	—	—	0.00	29.29	12.16	6.15	0.43	11.57	8.41	7.69

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARGX argenex SE	$53.2B	29.6×	32.4×	+59.46% (above 0%: growing)	+88.56% (above 0%: growing)	+537.51% (above 0%: growing)	90.60%	32.04%	Compare
RVMD Revolution Medicines, Inc.	$40.6B	— (loss-making)	— (loss-making)	−77.89% (below 0%: shrinking)	n/m	−69.98% (below 0%: shrinking)	100.00%	0.00%	Compare
ONC BeOne Medicines Ltd. - Sponsored ADR	$39.0B	62.6×	40.2×	+29.63% (above 0%: growing)	+143.68% (above 0%: growing)	+117.92% (above 0%: growing)	89.76%	19.06%	Compare
RPRX Royalty Pharma PLC	$34.3B	42.3×	21.9×	+16.50% (above 0%: growing)	−40.00% (below 0%: shrinking)	+31.57% (above 0%: growing)	100.00%	19.75%
ALNY Alnylam Pharmaceuticals, Inc.	$31.3B	39.5×	39.6×	+66.86% (above 0%: growing)	n/m	+152.82% (above 0%: growing)	76.88%	17.93%	Compare
ROIV Roivant Sciences Ltd.	$24.6B	— (loss-making)	— (loss-making)	−33.55% (below 0%: shrinking)	n/m	−29.99% (below 0%: shrinking)	80.31%	(25,380.93%)	Compare
INCY Incyte Corporation	$23.0B	13.9×	15.6×	+37.72% (above 0%: growing)	+39.71% (above 0%: growing)	+1,829.52% (above 0%: growing)	93.73%	41.69%	Compare
BNTX BioNTech SE Sponsored ADR	$22.7B	— (loss-making)	— (loss-making)	−58.53% (below 0%: shrinking)	n/m	−342.04% (below 0%: shrinking)	8.14%	(897.82%)	Compare
GMAB Genmab A/S Sponsored ADR	$22.6B	29.1×	21.0×	+24.86% (above 0%: growing)	−9.26% (below 0%: shrinking)	−7.69% (below 0%: shrinking)	92.73%	32.47%	Compare
Median of peers	$28.0B	29.6×	32.4×	+27.24%	+64.14%	+55.12%	90.18%	18.50%

All 614 Biotechnology stocks →

Royalty Pharma PLC (RPRX) key facts

Strength: Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
Royalty Pharma PLC (RPRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RPRX traded at $61.29, a market capitalization of $34.3 billion.
Royalty Pharma PLC pays an annual dividend of $0.93 per share, a yield of 1.51%, with a payout ratio of 63.8%.
Return on equity was 7.69% and debt-to-equity 0.92.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.61 (distress zone) for fiscal 2025.